Cargando…

Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study

INTRODUCTION: Patients with pulmonary tuberculosis (TB) sometimes show persistent severe inflammation for more than 1 month, even if TB treatment is effective. Although this inflammation can be improved through continuous antituberculous therapy, the risk factors for persistent inflammation remain u...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimoda, Masafumi, Yoshiyama, Takashi, Okumura, Masao, Tanaka, Yoshiaki, Morimoto, Kozo, Kokutou, Hiroyuki, Osawa, Takeshi, Furuuchi, Koji, Fujiwara, Keiji, Ito, Koki, Yoshimori, Kozo, Ohta, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276154/
https://www.ncbi.nlm.nih.gov/pubmed/35583541
http://dx.doi.org/10.1097/MD.0000000000029297
_version_ 1784745654961045504
author Shimoda, Masafumi
Yoshiyama, Takashi
Okumura, Masao
Tanaka, Yoshiaki
Morimoto, Kozo
Kokutou, Hiroyuki
Osawa, Takeshi
Furuuchi, Koji
Fujiwara, Keiji
Ito, Koki
Yoshimori, Kozo
Ohta, Ken
author_facet Shimoda, Masafumi
Yoshiyama, Takashi
Okumura, Masao
Tanaka, Yoshiaki
Morimoto, Kozo
Kokutou, Hiroyuki
Osawa, Takeshi
Furuuchi, Koji
Fujiwara, Keiji
Ito, Koki
Yoshimori, Kozo
Ohta, Ken
author_sort Shimoda, Masafumi
collection PubMed
description INTRODUCTION: Patients with pulmonary tuberculosis (TB) sometimes show persistent severe inflammation for more than 1 month, even if TB treatment is effective. Although this inflammation can be improved through continuous antituberculous therapy, the risk factors for persistent inflammation remain unclear. Therefore, we sought to study the characteristics of patients with persistent severe inflammation. MATERIALS AND METHODS: We retrospectively analyzed 147 hospitalized adult patients with C-reactive protein (CRP) levels of 5 mg/dL or more on admission to Fukujuji Hospital from April 2019 to March 2021. The patients were divided into 2 groups: 40 patients (27.2%) had CRP levels of 5 mg/dL or more at 4 weeks after admission (persistent inflammation group), and 107 patients (72.8%) had CRP levels that fell below 5 mg/dL within 4 weeks of admission (improved inflammation group). RESULTS: The median CRP level on admission in the persistent inflammation group was 10.8 mg/dL (interquartile range 9.1–14.5), which was higher than that in the improved inflammation group (median 8.2 mg/dL [6.5–12.1], P = .002). Patients in the persistent inflammation group had a higher prevalence of large cavities, defined as cavities ≥4 cm in diameter, on chest computed tomography (CT) (n = 20 [50.0%] vs n = 12 [11.2%], P < .001). DISCUSSION AND CONCLUSIONS: This study showed that 27.2% of patients who had high or moderate inflammation on admission did not achieve low CRP levels within 4 weeks after admission. Risk factors for persistent severe inflammation in patients with TB were presence of a large cavity (cavity diameter ≥4 cm) on chest CT and a high CRP level on admission. Therefore, in a patient with a large cavity on chest CT and/or CRP ≥9.0 mg/dL on admission, long-term inflammation may occur despite antituberculous therapy if other diseases are ruled out.
format Online
Article
Text
id pubmed-9276154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92761542022-07-13 Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study Shimoda, Masafumi Yoshiyama, Takashi Okumura, Masao Tanaka, Yoshiaki Morimoto, Kozo Kokutou, Hiroyuki Osawa, Takeshi Furuuchi, Koji Fujiwara, Keiji Ito, Koki Yoshimori, Kozo Ohta, Ken Medicine (Baltimore) 6700 INTRODUCTION: Patients with pulmonary tuberculosis (TB) sometimes show persistent severe inflammation for more than 1 month, even if TB treatment is effective. Although this inflammation can be improved through continuous antituberculous therapy, the risk factors for persistent inflammation remain unclear. Therefore, we sought to study the characteristics of patients with persistent severe inflammation. MATERIALS AND METHODS: We retrospectively analyzed 147 hospitalized adult patients with C-reactive protein (CRP) levels of 5 mg/dL or more on admission to Fukujuji Hospital from April 2019 to March 2021. The patients were divided into 2 groups: 40 patients (27.2%) had CRP levels of 5 mg/dL or more at 4 weeks after admission (persistent inflammation group), and 107 patients (72.8%) had CRP levels that fell below 5 mg/dL within 4 weeks of admission (improved inflammation group). RESULTS: The median CRP level on admission in the persistent inflammation group was 10.8 mg/dL (interquartile range 9.1–14.5), which was higher than that in the improved inflammation group (median 8.2 mg/dL [6.5–12.1], P = .002). Patients in the persistent inflammation group had a higher prevalence of large cavities, defined as cavities ≥4 cm in diameter, on chest computed tomography (CT) (n = 20 [50.0%] vs n = 12 [11.2%], P < .001). DISCUSSION AND CONCLUSIONS: This study showed that 27.2% of patients who had high or moderate inflammation on admission did not achieve low CRP levels within 4 weeks after admission. Risk factors for persistent severe inflammation in patients with TB were presence of a large cavity (cavity diameter ≥4 cm) on chest CT and a high CRP level on admission. Therefore, in a patient with a large cavity on chest CT and/or CRP ≥9.0 mg/dL on admission, long-term inflammation may occur despite antituberculous therapy if other diseases are ruled out. Lippincott Williams & Wilkins 2022-05-20 /pmc/articles/PMC9276154/ /pubmed/35583541 http://dx.doi.org/10.1097/MD.0000000000029297 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 6700
Shimoda, Masafumi
Yoshiyama, Takashi
Okumura, Masao
Tanaka, Yoshiaki
Morimoto, Kozo
Kokutou, Hiroyuki
Osawa, Takeshi
Furuuchi, Koji
Fujiwara, Keiji
Ito, Koki
Yoshimori, Kozo
Ohta, Ken
Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title_full Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title_fullStr Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title_full_unstemmed Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title_short Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study
title_sort analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: an observational study
topic 6700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276154/
https://www.ncbi.nlm.nih.gov/pubmed/35583541
http://dx.doi.org/10.1097/MD.0000000000029297
work_keys_str_mv AT shimodamasafumi analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT yoshiyamatakashi analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT okumuramasao analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT tanakayoshiaki analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT morimotokozo analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT kokutouhiroyuki analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT osawatakeshi analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT furuuchikoji analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT fujiwarakeiji analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT itokoki analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT yoshimorikozo analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy
AT ohtaken analysisofriskfactorsforpulmonarytuberculosiswithpersistentsevereinflammationanobservationalstudy